In an in vitro study with TCI, VeCollal® collagen technology stimulated the fibroblasts cells to increase collagen synthesis by approximately 135%. Fiberblasts maintain structural integrity of connective tissues including production of epithelial cells, hence skin and joints.
Detailed clinical trial reports and results will be released in the April of 2022.